Bristol-Myers Squibb is committed to helping you and your patients throughout their treatment with EMPLICITI. For information, tools, and support on the use of EMPLICITI, refer to the list of resources featured below.
Dosing and Ordering Guide
A reference guide for dosing, ordering, and product returns, plus support services for you and your patients.Read now
Find a list of distributors to physician offices, hospitals, and infusion centers.
An NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®) Category 1 treatment option for
previously treated multiple myeloma
*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.4.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 25, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.
†The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- EMPLICITI with lenalidomide and dexamethasone is associated with the following Warnings and Precautions: Infusion Reactions, Infections, Second Primary Malignancies, Hepatotoxicity, Interference with Determination of Complete Response, Pregnancy/Females and Males of Reproductive Potential, and Adverse Reactions.
Please see detailed Important Safety Information below.
Committed to responding to your questions within 24 hours or less.
Call the support center at 1-844-EMPLICITI
8 AM to 8 PM ET, Monday to Friday.
Our goal is to respond within one business day.